NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

What Happened NeuroOne Medical Technologies Corporation (NMTC) filed an 8-K (May 4, 2026) reporting that Nasdaq’s Listing Qualifications Staff notified the company on April 30, 2026 that it had regained compliance with the $1.00 minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2). The company had previously received a deficiency letter on May 6, 2025 after its closing bid price was below $1.00 for 30 consecutive business days.

Key Details

• Nasdaq deficiency letter received: May 6, 2025 (closing bid price < $1.00 for 30 consecutive business days).
• Regained compliance notice received from Nasdaq Staff: April 30, 2026.
• Reason for compliance: closing bid price of NeuroOne’s common stock was $1.00 or greater for the prior 10 consecutive business days.
• Matter status: Nasdaq indicated the company is in compliance and the matter is closed.

Why It Matters Regaining compliance with the $1.00 bid-price rule means NeuroOne met Nasdaq’s minimum listing standard on the date noted and Nasdaq closed the deficiency matter. For investors, this preserves the company’s continued inclusion on the Nasdaq Capital Market (avoiding delisting actions tied to this specific bid-price deficiency), which supports ongoing market visibility and trading access for NMTC shares.